Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2013 - 2024)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Notes Payables of $77000.0 for Q2 2024, up 50.52% year-over-year from $51157.0 in Q3 2023, and down 59.43% quarter-over-quarter from $189818.0 in Q1 2024.
Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2013 - 2024) Analysis & Trends
Corbus Pharmaceuticals Holdings' Notes Payables history runs 12 years deep, the most recent figure standing at $77000.0 for Q2 2024.
- In Q2 2024, Notes Payables rose 50.52% year-over-year to $77000.0; the TTM figure through Jun 2024 stood at $77000.0 (up 50.52% YoY), while the FY2023 annual figure was $301000.0, down 14.81% from the prior year.
- Notes Payables for Q2 2024 stood at $77000.0, down from $189818.0 in the prior quarter.
- The five-year high for Notes Payables was $803000.0 in Q1 2021, with the low at $36868.0 in Q3 2023.
- The 5-year median for Notes Payables is $252129.0 (2023), against an average of $350738.6.
- Peak annual rise in Notes Payables reached 449.86% in 2021, while the deepest fall reached 83.24% in 2021.
- Corbus Pharmaceuticals Holdings' Notes Payables stood at $797000.0 in 2020, then decreased by 3.65% to $767938.0 in 2021, then slumped by 53.99% to $353323.0 in 2022, then decreased by 14.81% to $301000.0 in 2023, then slumped by 74.42% to $77000.0 in 2024.
- Business Quant data shows CRBP's Notes Payables at $77000.0 in Q2 2024, $189818.0 in Q1 2024, and $301000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 189,818.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 36,868.00 |
| Jun 30, 2023 | 51,157.00 |
| Mar 31, 2023 | 203,258.00 |
| Dec 31, 2022 | 353,323.00 |
| Sep 30, 2022 | 133,710.00 |
| Jun 30, 2022 | 133,710.00 |
| Mar 31, 2022 | 440,815.00 |
| Dec 31, 2021 | 767,938.00 |
| Sep 30, 2021 | 126,857.00 |
| Jun 30, 2021 | 599,000.00 |
| Mar 31, 2021 | 803,000.00 |
| Dec 31, 2020 | 797,000.00 |
| Sep 30, 2020 | 757,000.00 |
| Jun 30, 2020 | 108,936.00 |
| Mar 31, 2020 | 432,905.00 |
| Dec 31, 2019 | 752,659.00 |
| Jun 30, 2019 | 99,333.00 |